Dexrazoxane for childhood cancer patients – ready for prime time?
Episode Description
Summarize the paper by Asselin et al and review the risks of therapy-related cardiomyopathy and evidence supporting dexrazoxane use in pediatric oncology.
We use cookies to run this site. Analytics cookies help us understand how you use it and are off until you say yes. You can change your mind at any time from the privacy preferences icon at the bottom right.We use cookies to run this site and to understand how it's used. You can opt out at any time from the privacy preferences icon at the bottom right. Cookie policy